Skip to content
Longterm Wiki
grant

Eiger InnoTherapeutics — Lonafarnib and Pegylated Interferon Lambda

Metadata

Source Tablegrants
Source IDZ8dWZHr-BZ
Descriptionto Eiger InnoTherapeutics, $3,000,000, 2024-04
Source URLcoefficientgiving.org/grants/
ParentULjDXpSLCI
Children
CreatedMar 12, 2026, 5:54 AM
UpdatedMar 19, 2026, 8:57 PM
SyncedMar 19, 2026, 8:57 PM

Record Data

idZ8dWZHr-BZ
organizationIdCoefficient Giving(organization)
granteeIdEiger InnoTherapeutics
orgEntityIdCoefficient Giving(organization)
orgDisplayName
granteeEntityId
granteeDisplayNameEiger InnoTherapeutics
nameEiger InnoTherapeutics — Lonafarnib and Pegylated Interferon Lambda
amount3000000
currencyUSD
period
date2024-04
status
sourcecoefficientgiving.org/funds/
notes[Scientific Research] Open Philanthropy recommended an investment of $3,000,000 in Eiger InnoTherapeutics, a new company founded by Professor Jeffrey S. Glenn, that has acquired the rights to two drugs, lonafarnib and pegylated interferon lambda. The company will develop Lonafarnib for use against h
programIdB4pZkOtjSk
dataSourceId

Source Check Verdicts

confirmed95% confidence

Last checked: 4/3/2026

[deterministic-row-match] Deterministic match: grantee, amount, date matched in source snapshot (2714 rows)

Debug info

Thing ID: Z8dWZHr-BZ

Source Table: grants

Source ID: Z8dWZHr-BZ